Anvisa approves five semaglutide pens, ending Novo Nordisk's market exclusivity in Brazil

Brazil's regulatory agency, Anvisa, has authorized five new semaglutide pens from Hypera, Sandoz, and Sun Pharma. This move breaks the market exclusivity previously held by Novo Nordisk following the expiration of patent protections in March. The entry of these competitors is expected to increase supply and potentially lower costs for weight-loss treatments in the Brazilian market.